I will also highlight the continued strong performance of Roxadustat in China and the potential for Roxadustat development for the treatment of anemia due to lower-risk myelodysplastic syndrome. Then ...

Its portfolio includes roxadustat, approved for treating anemia in chronic kidney disease patients across multiple regions, and FG-3246, an innovative antibody-drug conjugate targeting CD46 in ...

It’s associated with increased rates of infant mortality, ADHD, dementia, depression, coronary heart disease and anemia. And ...

Atrial arrhythmias were found in 26% of patients with sickle cell disease (SCD), with a significant association with stroke history. Early detection and treatment of atrial arrhythmias may help ...

The global chemotherapy-induced anemia market, valued at USD 2.25 billion in 2022, is expected to grow at a CAGR of 7.2%, ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

JACKSON, Miss. (WLBT) - On Tuesday, the American Red Cross launched a fight against Sickle Cell Anemia by hosting blood ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting ...

People with SCD typically suffer from serious clinical consequences, which may include anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease, and ...

The Humane Society of Louisiana is addressing an increase in animals being dumped in New Orleans East. According to the ...

A University of Rochester hospital will open a patient study comparing the efficacy of SCD treatments to help families in ...

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...